CMG Pharmaceutical Co., Ltd.
🇰🇷South Korea
- Country
- 🇰🇷South Korea
- Ownership
- Public
- Established
- 2001-08-01
- Employees
- 282
- Market Cap
- -
- Website
- http://www.cmgpharma.co.kr
Clinical Trials
2
Active:0
Completed:1
Trial Phases
2 Phases
Phase 1:1
Phase 3:1
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (2 trials with phase data)• Click on a phase to view related trials
Phase 1
1 (50.0%)Phase 3
1 (50.0%)Evaluate the Efficacy and Safety of CMG190303 in Patients with Type 2 Diabetes and Dyslipidemia
Phase 3
Recruiting
- Conditions
- Type 2 DiabetesDyslipidemia
- Interventions
- Drug: CMG190303(Dapagliflozin/Rosuvastatin)Drug: Rosuvastatin/Dapagliflozin placebo
- First Posted Date
- 2025-01-13
- Last Posted Date
- 2025-01-15
- Lead Sponsor
- CMG Pharmaceutical Co. Ltd
- Target Recruit Count
- 240
- Registration Number
- NCT06772168
- Locations
- 🇰🇷
Hallym university gangnam medical center, Seoul, Korea, Republic of
🇰🇷Hallym university sungsim medical center, Anyang, Korea, Republic of
🇰🇷Buchon sejong hospital, Buchon, Korea, Republic of
Comparative Bioavailability Study of Aripiprazole 10 mg Oral Soluble Film vs Abilify® 10 mg Tablet in Healthy Volunteers
- First Posted Date
- 2015-07-17
- Last Posted Date
- 2016-03-24
- Lead Sponsor
- CMG Pharmaceutical Co. Ltd
- Target Recruit Count
- 36
- Registration Number
- NCT02501109
News
No news found